

Claims:

1. An antibody, or antigen binding fragment, which is capable of binding to PD-1, optionally isolated, having at least one light chain variable region incorporating the following CDRs:

LC-CDR1:	SGSSSNIKFNSVN	(SEQ ID NO:25)
LC-CDR2:	SNNQRPS	(SEQ ID NO:26)
LC-CDR3:	ASWDDYLRGTV	(SEQ ID NO:29) or
	ASWDDYYYGTI	(SEQ ID NO:28); and

having at least one heavy chain variable region incorporating the following CDRs:

HC-CDR1:	SYGMH	(SEQ ID NO:89) or
	GFTFSSYGMH	(SEQ ID NO:39)
HC-CDR2:	VISYDGSNKYYADSVKG	(SEQ ID NO:40)
HC-CDR3:	DYGAGPYYYGMDV	(SEQ ID NO:43) or
	DLGAGPYYYGKDV	(SEQ ID NO:42).

2. The antibody or antigen binding fragment of claim 1, comprising a heavy chain and a light chain variable region sequence, wherein:

the heavy chain sequence has at least 70% sequence identity to the heavy chain sequence of SEQ ID NO:15 or 14 (Figure 2), and

the light chain sequence has at least 70% sequence identity to the light chain sequence of SEQ ID NO:3 or 2 (Figure 1).

3. The antibody, or antigen binding fragment, of claim 1 or claim 2, wherein the antibody or antigen binding fragment specifically binds human or rhesus PD-1 over other members of the CD28 family.

4. The antibody, or antigen binding fragment, of any one of claims 1 to 3, wherein the antibody or antigen binding fragment is effective to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.

5. An antibody or antigen binding fragment, optionally isolated, which is capable of binding to PD-1, which is a bispecific antibody or a bispecific antigen binding fragment comprising (i) an antigen binding fragment according to any of one of claims 1 to 4, and (ii) an antigen binding domain which is capable of binding to a target protein other than PD-1.

6. The antibody, or antigen binding fragment, of claim 5, wherein the antigen binding domain which is capable of binding to a target protein other than PD-1 is capable of binding to one of TIM-3, LAG3, ICOS, CTLA4, BTLA or CD28.

5

7. An *in vitro* complex, optionally isolated, comprising an antibody, or antigen binding fragment, according to any one of claims 1 to 6 bound to PD-1.

10

8. A composition comprising the antibody or antigen binding fragment of any one of claims 1 to 6 and at least one pharmaceutically-acceptable carrier.

9. An isolated nucleic acid encoding the antibody or antigen binding fragment of any of one of claims 1 to 6.

15

10. A vector comprising the nucleic acid of claim 9.

11. A host cell comprising the vector of claim 10.

20

12. A method for making an antibody, or antigen binding fragment of any of one of claims 1 to 6 comprising culturing the host cell of claim 11 under conditions suitable for the expression of a vector encoding the antibody or antigen binding fragment, and recovering the antibody or antigen binding fragment.

25

13. An antibody or antigen binding fragment according to any of one of claims 1 to 6 for use in therapy, or in a method of medical treatment.

14. An antibody or antigen binding fragment according to any of one of claims 1 to 6 for use in the treatment of a T-cell dysfunctional disorder.

30

15. An antibody or antigen binding fragment or polypeptide according to any of one of claims 1 to 6 for use in the treatment of cancer.

16. An antibody or antigen binding fragment according to any of one of claims 1 to 6 for use in the treatment of an infectious disease.

17. Use of an antibody or antigen binding fragment according to any of one of claims 1 to 6 in the manufacture of a medicament for use in the treatment of a T-cell dysfunctional disorder.

18. Use of an antibody or antigen binding fragment according to any of one of claims 1 to 6 in the manufacture of a medicament for use in the treatment of cancer.

19. Use of an antibody or antigen binding fragment according to any of one of claims 1 to 6 in the manufacture of a medicament for use in the treatment of an infectious disease.

20. A method, *in vitro*, of enhancing T-cell function comprising administering an antibody or antigen binding fragment according to any one of claims 1 to 6 to a dysfunctional T-cell.

21. A method comprising contacting a sample containing, or suspected to contain, PD-1 with an antibody or antigen binding fragment according to any one of claims 1 to 6 and detecting the formation of a complex of antibody, or antigen binding fragment, and PD-1.

22. A method of diagnosing a disease or condition comprising contacting, *in vitro*, a sample from a subject with an antibody, or antigen binding fragment, according to any one of claims 1 to 6 and detecting the formation of a complex of antibody, or antigen binding fragment, and PD-1.

23. A method of selecting or stratifying a subject for treatment with PD-1 targeted agents, the method comprising contacting, *in vitro*, a sample from the subject with an antibody, or antigen binding fragment, according to any one of claims 1 to 6 and detecting the formation of a complex of antibody, or antigen binding fragment, and PD-1.

24. Use of an antibody, or antigen binding fragment, according to any one of claims 1 to 6 for the detection of PD-1 *in vitro*.

5 25. Use of an antibody, or antigen binding fragment, according to any one of claims 1 to 6 as an *in vitro* diagnostic agent.

26. A method for expanding a population of T cells, wherein T cells are contacted *in vitro* or *ex vivo* with an antibody or antigen binding fragment according to any one of claims 1 to 6.